Chinese mRNA Vaccine Developer Abogen Raises $300 Mln From SoftBank Vision Fund, Others

BEIJING — Chinese mRNA technology firm Suzhou Abogen Biosciences said on Monday it had raised $300 million from investors including SoftBank Group Corp’s Vision Fund to support the development of its potential COVID-19 shot and other drug candidates. Read More